NDA 203415 · Astellas
Xtandi
Enzalutamide · Oral · Androgen Receptor Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Aug 31, 2012
Approved uses
11
Original approval plus efficacy supplements
Registered trials
385
74 Phase 3, 82 recruiting
FAERS reports
58,866
36,319 serious, 11,400 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 28, 2026.
XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with: • castration-resistant prostate cancer. ( 1 ) • metastatic castration-sensitive prostate cancer. ( 1 ) • non‑metastatic castration‑sensitive prostate cancer with biochemical recurrence at high risk for metastasis. ( 1 )
Mechanism: Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits nuclear translocation of androgen receptors and their interaction with DNA. A major metabolite, N‑desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro , and decreased tumor volume in a mouse prostate cancer xenograft model.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 24, 2026 Supplement 26 · Efficacy LabelLetter
- Nov 16, 2023 Supplement 22 · Efficacy · priority review LabelLetter
- Sep 9, 2022 Supplement 19 · Efficacy LetterLabel
- Oct 23, 2020 Supplement 16 · Efficacy · priority review LetterLabel
- Dec 16, 2019 Supplement 15 · Efficacy · priority review LabelLetter
- Jul 13, 2018 Supplement 14 · Efficacy · priority review LabelLetter
- Jul 24, 2017 Supplement 11 · Efficacy LabelLetter
- Oct 20, 2016 Supplement 9 · Efficacy LabelLetter
- Jul 21, 2015 Supplement 5 · Efficacy LabelLetter
- Sep 10, 2014 Supplement 3 · Efficacy · priority review LabelLetter
- Aug 31, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewSummary ReviewLabel
1 products under this application
- XTANDI · ENZALUTAMIDE 40MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Enzalutamide" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyPivotal-lookingEnrolling by invitation
ExelixisIndustry
NCT07620574 · 5,000 participants (planned) · Start Jul 30, 2026 · Primary completion May 31, 2030
Drug: Cabozantinib; Zanzalintinib and 5 more · For: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) and 6 more
Sites: Bay Shore, New York; Kettering, Ohio; Memphis, Tennessee · 4 sites in all
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06320067 · 3,360 participants (planned) · Start Jun 11, 2024 · Primary completion Apr 2031
Drug: Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI) and 1 more · For: Prostate Cancer Metastatic
Sites: Barnsley, United Kingdom; Cambridge, United Kingdom; Exeter, United Kingdom · 18 sites in all
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06120491 · 1,898 participants · Start Nov 21, 2023 · Primary completion Sep 30, 2027
Drug: Saruparib; Placebo and 3 more · For: Metastatic Castration-Sensitive Prostate Cancer
Sites: Chandler, Arizona; Gilbert, Arizona; Phoenix, Arizona · 322 sites in all
- A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate CancerPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01212991 · 1,717 participants · Start Sep 16, 2010 · Primary completion Sep 30, 2013
Drug: Enzalutamide; Placebo · For: Prostate Cancer
Sites: Birmingham, Alabama; Tucson, Arizona; La Mesa, California · 269 sites in all
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsPivotal-lookingRecruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT05974774 · 1,600 participants (planned) · Start May 23, 2025 · Primary completion May 23, 2035
Drug: iMAB; cMAB · For: Prostate Cancer
Sites: Copenhagen, Denmark; Caen, France; Grenoble, France · 9 sites in all
- Pan Tumor Rollover StudyRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03899155 · 1,500 participants (planned) · Start Aug 9, 2019 · Primary completion Aug 25, 2029
Drug: Nivolumab; Ipilimumab and 17 more · For: Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Lynwood, California · 410 sites in all
- Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07751133 · 1,500 participants (planned) · Start Aug 28, 2026 · Primary completion Aug 1, 2029
Drug: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy · For: Prostate Cancer; mHSPC; mCRPC
Sites: Huddersfield, United Kingdom; Manchester, United Kingdom; Sutton, United Kingdom · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue10,332
- death7,715
- malignant neoplasm progression5,499
- prostatic specific antigen increased4,361
- asthenia4,207
- drug ineffective4,067
- hot flush3,932
- decreased appetite3,421
- nausea3,270
- dizziness3,172
- diarrhoea2,813
- back pain2,307
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 244 |
| 2013 | 2,555 |
| 2014 | 4,441 |
| 2015 | 5,923 |
| 2016 | 7,914 |
| 2017 | 10,285 |
| 2018 | 7,756 |
| 2019 | 3,394 |
| 2020 | 2,641 |
| 2021 | 2,409 |
| 2022 | 2,608 |
| 2023 | 2,329 |
| 2024 | 2,508 |
| 2025 | 2,634 |
| 2026 | 1,225 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xtandi (Enzalutamide)
2024 spending
$3.40B
Beneficiaries
35,367
255,669 claims
Per beneficiary
$96,157
$150.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,968,567,948 |
| 2021 | $2,411,262,130 |
| 2022 | $2,436,795,703 |
| 2023 | $2,601,510,278 |
| 2024 | $3,400,769,229 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Morris MJ, Castellano D, Herrmann K, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J, Mateo J, Fizazi K, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, et al. · Lancet 2022 · Meta-Analysis
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. · J Clin Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
- Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.
Fizazi K, Chi KN, Shore ND, et al. · Ann Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
Sponsor: Astellas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.